A horse at Hawthorne was euthanized Nov. 26 and a necropsy revealed the horse had EHV-1. It is the fourth horse to die of the disease during the Hawthorne fall meet.
On Nov. 16, track officials confirmed a horse who died Nov. 14 and one other ailing horse had tested positive for EHV-1. The deceased horse is the third confirmed death from EHV-1 during the outbreak.
Following discussions with state veterinarians, the Department of Agriculture, and consultants from the Kentucky Department of Agriculture, the decision was made to put a quarantine of the affected barn in place.
Calder restricts training hours, racing entry of horses in two barns that may have been exposed to neurological form of equine herpesvirus type-1 (EHV-1). Regulations expected to last into early January.
In anticipation of the quarantine at Pimlico Race Course being lifted next week, 11 trainers entered 14 horses Friday for the Feb. 8 card at Laurel Park.
Horses stabled in a second Churchill Downs barn placed under quarantine by the Kentucky Department of Agriculture because of confirmed cases of equine herpes virus at the track will be allowed to return to limited training on May 23.
A restriction on horses shipping into Philadelphia Park from Penn National due to three horses testing positive for equine herpesvirus type 1 (EHV-1) at Penn may be lifted early next week, officials for both Pennsylvania racetracks said Wednesday.
A mare or mares imported from North America to Victoria are believed to be at the center of the latest outbreaks of the equine herpes virus or Equine Rhinopneumonitis virus (EHV-1) in Australia.
Most Popular Stories
- Travers Favorite Bayern Arrives at Saratoga
- King's Bishop: Coup de Grace vs. Wildcat Red
- Heated Rivalry Rekindled in Del Mar Handicap
- Ready to Act, Daring Kathy Vie at Woodbine
- Starstruck Heads Cast in Monmouth's Violet
- Shared Belief Looking to Retain His Throne
- Big Three Clash in Rich Travers Stakes
- Better Lucky Sticks With Dirt for Ballerina
- Australia Easy Juddmonte International Winner
- FDA Sends Warning Letter to Compounding Firm